menu search

Pharvaris shares soar on positive top-line phase 2 data from rapide-1 study as it releases 3q results

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema...

December 8, 2022, 11:34 am

Zynerba pharmaceuticals announces positive long-term data from phase 2 inspire trial at annual meeting of the american college of neuropsychopharmacology

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacolog...

December 5, 2022, 8:36 am

Dow jones newswires: gsk phase 3 trial for jemperli endometrial cancer treatment met primary endpoint

The trial showed a statistically significant and clinically meaningful improvement in investigator-asse...

December 2, 2022, 7:56 am

Axsome therapeutics announces axs-05 achieves primary endpoint in the accord phase 3 trial in alzheimer’s disease agitation

AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus pl...

November 28, 2022, 11:35 am

Gilead (gild) breast cancer drug trodelvy improves survival

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meani...

September 8, 2022, 1:32 pm

Mgc pharmaceuticals boss hails long covid study success as 'real breakthrough'

Roby Zomer, the managing director of MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC), hailed as a ‘real breakthrough' results from a clinical ...

July 14, 2022, 2:51 am

Veru: the signs seem to point to an eua for sabizabulin

Veru ought to find out very soon whether its lead asset, Sabizabulin, has been awarded an Emergency Use Authorization to treat hospitalized COVID pati...

July 13, 2022, 12:04 pm

Aldeyra's reproxalap hits primary goals in dry eye disease chamber crossover trial

Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an in...

July 12, 2022, 9:03 am

Roche-ac immune's crenezumab fails to show benefit in sub-set of alzheimer's patients

Roche Holdings AG (OTC: RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic...

June 16, 2022, 8:36 am

Pfizer (pfe) covid pill ineffective in standard risk patients

Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study sho...

June 15, 2022, 4:58 pm

Optinose stock moves higher on positive second chronic sinusitis phase 3 trial

Optinose Inc (NASDAQ: OPTN) announced the statistically significant benefits of XHANCE in the ReOpen...

June 13, 2022, 11:21 am

Dbv technologies shares jump on positive data from peanut allergy trial in toddlers

DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its ...

June 8, 2022, 7:24 am

Altamira's drug-free nasal spray shows benefit in house dust mite study

Altamira Therapeutics Ltd (NASDAQ: CYTO) announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic ...

May 20, 2022, 11:41 am

See here why recently listed eliem therapeutics shares are plummeting

Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve ...

April 25, 2022, 9:06 am

Allergy therapeutics to present new data on lead vaccines this week

Allergy Therapeutics PLC (AIM:AGY) said it will publish new data on its three main vaccine developments at the joint WAO & BSACI conference in Edinbur...

April 25, 2022, 3:20 am

Aptinyx shares tank on disappointed data from mid-stage diabetic peripheral neuropathy study

Aptinyx Inc (NASDAQ: APTX) shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropath...

April 7, 2022, 9:36 am

Why theravance biopharma stock is trading lower after hours

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0...

April 4, 2022, 4:39 pm

Why i'm buying walmart in march

Our seasonal portfolio's February short position on Walmart has worked out so far, but March is statistically<...

February 24, 2022, 11:24 pm


Search within

Pages Search Results: